Analysis on the application value of FIRST simplified frailty scale score in patients with newly diagnosed mul-tiple myeloma
YAO Qiong
WANG Xinwei
YANG Hui
LI Linyu
ZHAO Jie
HE Shaolong
TIAN Weiwei
Abstract：Objective To analyze the application value of FIRST simplified frailty scale score in patients with newly diagnosed multiple myeloma(NDMM).Methods The clinical data of 131 patients with NDMM who were admitted to the Third Hospital of Shanxi Medical University from July 1,2014 to December 31,2021 were retrospectively analyzed.The patients were divided into frailty group(50 cases)and non-frailty group(81 cases)according to different FIRST simplified frailty scale scores.The therapeutic effect,cumulative incidence of early grade ≥3 infection and survival prognosis were compared between the patients in the two groups.Subgroup analysis was performed for the patients receiving bortezomib-based induction therapy scheme.Results There was no significant difference in the proportion of the patients with therapeutic effect being more than or equal to very good partial response(VGPR)between the two groups(45.68％vs 36.00％,P＞0.05).There were 26 cases(52.00％)and 27 cases(33.33％)of early grade ≥3 infection in the frailty group and the non-frailty group,respectively.The prognosis of the patients related to early grade ≥3 infection in the frailty group was worse than that in the non-frailty group(log-rank test:x2=4.472,P=0.020).The median overall survival(OS)time and median progression-free survival(PFS)time in the frailty group was shorter than that in the non-frailty group(36 months vs 81 months;16 months vs 34 months),and the survival prognosis of the non-frailty group was significantly better than that of the frailty group(P＜0.05).Among the 100 patients receiving the therapy of bortezomib-based induction scheme,both the median OS time and the median PFS time in the frailty group was shorter than that in the non-frailty group(34 months vs 84 months;15 months vs 33 months),and the survival prognosis of the non-frailty group was significantly better than that of the frailty group(P＜0.05).Conclusion FIRST simplified frailty scale score has relatively good application value for patients with NDMM.
Keywords：Multiple myelomaFIRST simplified frailty scaleFrailtyInfectionPrognosis
Publication Date：2024-02-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 186-191 )